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The neuromodulator oxytocin, since its first synthesis by du Vigneaud in 1953, has
mainly been associated with beneficial physiological effects, as well as positive social
and emotional behaviors. This overall positive picture of oxytocin as the “love-, cuddle-,
or bonding-hormone” has repeatedly been challenged since then. Oxytocin-induced
effects that would be perceived as negative by the individual, such as increased
anxiety or potentiation of stress-induced ACTH release, as well as the regulation of
negative approach-related emotions, such as envy and schadenfreude (gloating) have
been described. The general consent is that oxytocin, instead of acting unidirectional,
induces changes in the salience network to shift the emphasis of emotional contexts,
and therefore can, e.g., produce both anxiolytic as well as anxiogenic behavioral
outcomes. However, the underlying mechanisms leading to alterations in the salience
network are still unclear. With the aim to understand the manifold effects of oxytocin
on a cellular/molecular level, a set of oxytocin receptor-coupled signaling cascades
and downstream effectors regulating transcription and translation has been identified.
Those oxytocin-driven effectors, such as MEF2 and CREB, are known modulators of
the neuronal and glial cytoarchitecture. We hypothesize that, by determining cellular
morphology and connectivity, MEF2 is one of the key factors that might contribute to
the diverse behavioral effects of oxytocin.
Keywords: oxytocin, salience, MEF2, anxiety, stress, cellular morphology
INTRODUCTION
The neuropeptide oxytocin is mainly produced in the hypothalamic paraventricular (PVN) and
supraoptic nuclei (SON), it is released from magnocellular cells by axonal and somatodendritic
release, and into the periphery via axonal projections (1). Peripheral axonal release into the blood
stream and central dendritic release can occur in an orchestrated or independent manner (2–4) and
produces a variety of behavioral effects, ranging from anxiety, fear conditioning and fear extinction,
social exploration and recognition to aggressive behavior (5). After taking differences in dosing,
timing, species, or central vs. peripheral release into account, we are still left with some puzzling
inconsistencies regarding the behavioral effects of oxytocin [for review see (1)]. The concept to
explain and interpret the behavioral effects of oxytocin is centered around a change in salience
of emotional contexts (6–8), rather than unidirectional influences on certain types of behavior
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(e.g., anxiety). Our aim is to establish a coherent mechanistic
understanding of the intracellular processes that underlie this
change in emotional salience and therefore the effects on
opposing behavioral outcomes.
ALLEVIATING BEHAVIORAL EFFECTS OF
OXYTOCIN
In rodents, the level of anxiety can be assessed by testing the
exploratory drive vs. the fear of open and brightly lit spaces,
as it is done in the elevated plus maze (EPM) or Light Dark
Box (LDB). In previous publications, we have established that
an infusion of synthetic oxytocin directly into the PVN of
male and female rats reduces anxiety-like behavior for at least
4 h, i.e., increases the time spent in the open arms or lit
compartment of the EPM and LDB, respectively (9–12). The
endogenous release of oxytocin within the PVN can be triggered
in male and female rats by various stimuli (13, 14). For instance,
mating leads to a similar anxiolysis as observed with synthetic
oxytocin infusions, indicating the behavioral valence of synthetic
oxytocin (15, 16). In female prairie voles, intra-PVN infusions
of oxytocin reduce anxiety-like behavior by activating local
GABAergic neurons, which dampen the stress-induced activity
of CRF-positive neurons and subsequent corticosterone release
(17). As oxytocin receptors are also expressed on CRF-positive
neurons (18), it not only acts via GABAergic inhibition, but
also relies on direct oxytocin receptor-coupled modulation of
stress-induced CRF transcription in the PVN of male rats as well
(19). The interplay between oxytocin and the CRF system is not
restricted to the PVN, as oxytocin receptor interneurons in the
medial prefrontal cortex are responsible for anxiolysis in male
mice, whereas in female mice they act pro-social by GABAergic
inhibition of CRF receptor 1 expressing neurons (20, 21).
In a similar manner, infusions into the central amygdala
reduce anxiety as well (22), and evoked release of endogenous
oxytocin attenuates freezing in fear-conditioned mice (23) by
acting on a local GABAergic inhibitory output circuit (24, 25).
The type of fear response displayed, i.e., either startle response or
active escape, is orchestrated by glutamatergic projections from
the basolateral amygdala to oxytocin receptor positive cells in
the central amygdala of mice and humans (26). Oxytocin also
attenuates social fear expression in male, virgin and lactating
female mice (27, 28), and cued fear extinction in male mice (29).
Those positive “dampening” or “alleviating” effects of
oxytocin have been well-established in literature, so much, that
a comprehensive list of all studies would be beyond the scope
of this review [for extended discussion see (1)]. However, not
all findings are in line with such a “positive” image of oxytocin.
Depending on the context, oxytocin can produce opposing, more
adverse or negative effects on behavior.
ADVERSE BEHAVIORAL EFFECTS OF
OXYTOCIN
However, well-described the alleviating effects of oxytocin
might be, potentiating effects of oxytocin on the stress
response and increased anxiety have to be reflected to
generate a comprehensive understanding. For instance,
when peripheral oxytocin levels are increased chronically
by subcutaneous infusion in male rats over the course of 14
days, ACTH and corticosterone levels, and adrenal weights
are increased, indicating a potentiating effect of oxytocin
on the HPA axis, and therefore the stress response (30). In
addition, single subcutaneous injections transiently increase
plasma ACTH and corticosterone levels in male rats (31),
but decrease corticosterone levels 6 h after the injection
without affecting ACTH levels. In an ex vivo setting, i.e.,
isolated hemipituitaries from male rats, oxytocin potentiated
the CRF-induced ACTH release (32). In an in vivo setting,
peripheral oxytocin secretion is modestly influenced by
the activated HPA axis, i.e., plasma corticosterone levels;
however, corticosterone levels amplified stress-induced
oxytocin release within the PVN (33). Those data delineate
oxytocin as a modulator of activated systems like the HPA
axis instead of acting as a solitary driving force. However,
a recent study conducted in wild chimpanzees failed to
associate oxytocinergic system activity with increased stress
and aggression during out-group conflict (34), which is
seemingly in contrast to predictions made by the social
salience hypothesis of oxytocin. However, whether urinary
oxytocin and cortisol levels reflect central or plasma
concentrations has yet to be determined, as a random
discrepancy between those body-fluids might be the cause for the
failed association.
In addition, timing and dosage seem to be key aspects that
orchestrate the functional outcome. For instance, in a mouse
model of chronic oxytocin infusion via osmotic minipumps,
a low dose of chronic oxytocin (1 ng/0.2 µl/h) alleviated
the effects of chronic stress, such as thymus atrophy, adrenal
hypertrophy and decreased in vitro adrenal ACTH sensitivity;
whereas a high dose (10 ng/0.2 µl/h) increased anxiety-
like behavior in male mice (35). The increased anxiety was
concomitant with a decreased expression of oxytocin receptors
in the septum, likely as part of a negative feedback regulation,
indicating this region as one important regulatory region for
oxytocin-driven anxiety. However, the expression of fear in
socially defeated male mice is positively associated with the
expression level of oxytocin receptors and its coupling to
the MAP kinase pathway in the lateral septum (36). When
knocked down, the level of fear displayed by socially defeated
mice toward their defeater was diminished, compared to mice
where oxytocin receptors were overexpressed. The authors
conclude that oxytocin does not have a unidirectional influence
on anxiety, but rather changes the salience or valence of
an emotional context (36). Another study revealed a full
rescue of socially transmitted fear in unfamiliar male mice
together with an enhanced cellular activity within the anterior
cingulate cortex after acute intranasal oxytocin administration
(37). To the contrary, the same study also investigated the
effects of chronic oxytocin administration, which led to long-
term facilitation of observational fear. Interestingly, none of
these manipulations affected fear acquired as a result of direct
experience with the stressor, but only socially transmitted fear.
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Hence, these results emphasize the role of oxytocin in context-
dependent empathy.
Effects on empathy and context-dependent social cues
have also been studied in human probands that received
intranasal oxytocin. Those studies found increased aggression
toward game partners in the “social orientation paradigm”
(38), increased envy and schadenfreude or gloating in a
game of chance (39), and even increased anxiety, indicated
by an enhanced startle response after unpredictable
threats (40).
Most of the above-mentioned studies interpret their
data according to the salience hypothesis stating that
oxytocin increases the perception of social stimuli dependent
on the context, instead of acting unidirectional on any
behavior. Thus, if oxytocin is not a pure anxiolytic,
analgesic, or anti-stress hormone, but rather shifts
the salience of an emotional context, changes in the
activity of the salience network must be detectable (see
Figure 1).
OXYTOCIN AND THE SALIENCE
NETWORK
In order to understand the multitude of behavioral effects
of oxytocin, a theoretical framework has been proposed that
includes a prominent role for oxytocin-dopamine-interactions in
regulating the salience of social cues (41). For instance, a recent
study conducted in titi monkeys found increased anxiety and a
trend toward increased glucose uptake in regions of the salience
network. Specifically, glucose uptake tended to increase in the
SON and caudate nucleus, in male animals treated chronically
with intranasal oxytocin from 12 to 18 months of age (42). In
addition to the SON and caudate nucleus, the salience network
consists of other brain regions that have already been associated
with oxytocinergic effects and that express the oxytocin receptor,
like the anterior cingulate cortex, lateral septum, striatum, medial
prefrontal cortex, hippocampus, amygdala, nucleus accumbens,
and PVN (42). The significance of the salience network for
psychiatric disorders has been shown by a very comprehensive
meta-analysis that included more than 7,000 individuals with
psychiatric diagnoses ranging from depression, bipolar disorder,
schizophrenia, or obsessive-compulsive disorder, to anxiety
disorders (43). In each of those disorders, changes in myelin
protein expression (44, 45), decreased gray and white matter
volume (46), and loss of connectivity have been detected in core
regions of the salience network, like the anterior cingulate cortex
or medial prefrontal cortex, leading to impairments of cognitive
control, which has been proposed as a diagnostic feature across
the above-mentioned psychiatric disorders (47).
Besides alterations in oligodendrocyte-based myelin
formation or damage, reduced gray matter volume and
connectivity can be caused either by morphological changes
of neurons (i.e., increased or decreased synapse formation)
or by reduced neuronal survival rates. Consequentially,
factors that influence those two aspects, and are triggered
by oxytocin could be the sought after molecular substrates
of the behavioral effects of oxytocin. In search for those
factors, we investigated the signaling cascades coupled to the
oxytocin receptor.
OXYTOCIN AND MEF2
A first clue can be drawn from the apparent universal
involvement of the MAP kinase pathway in the above-described
contexts, e.g., the fear enhancing effects in the lateral septum (36),
or the anxiolytic and anti-stress effects in the PVN (9, 10, 19).
Potential targets of the MEK1/2-ERK1/2 pathway are on the
one hand the transcription factor CREB, which is involved in
oxytocin-induced spatial memory formation (48) and CRF gene
transcription (19). On the other hand, the transcription factor
myocyte enhancer factor 2 (MEF2), which has been shown to be
directly activated following oxytocin receptor activation (49, 50)
via the calcium-dependent phosphatase calcineurin (51).MEF2 is
a main regulator of neuronal morphology, survival, connectivity,
plasticity, and metaplasticity (52–54). CREB and MEF2 can act
independently, but have also been shown to bind in concert to
the synaptic response element (SARE), an enhancer sequence
found upstream of many neuronal plasticity-related genes (55,
56). While we have identified a MEF2 binding sequence in
the oxytocin receptor promoter with in silico prediction tools,
there is no recent evidence available, whether activated MEF2
alters the transcription of the Oxtr gene. Decreased MEF2
levels and increased phosphorylation levels, i.e., decreased gene
transcription, have been found in mice that underwent fear
conditioning and spatial memory tasks. In contrast, increasing
MEF2 levels and dephosphorylation prevented the formation of
spatial memory and associated increase in spine density. These
findings suggest that MEF2-mediated transcription constrains
memory formation by interfering with neuronal plasticity (57).
MEF2 AND NEURONAL CONNECTIVITY
Neuronal plasticity and connectivity is governed by the ability
of the neurons to adapt their cellular morphology to the
momentary requirements, i.e., induce neurite outgrowth and
retraction. Both factors, CREB and MEF2 have been shown to
actively regulate neurite outgrowth (58, 59) and thus influence
the formation of synapses (60, 61). Those oxytocin-induced
cellular effects can depend on MEF2 expression levels as the
transcription factor is known to be a regulator of metaplasticity,
i.e., it determines how neurons respond to stimuli by shifting
plasticity thresholds (54). Moreover, mutated MEF2 has been
associated with Rett-like syndrome (62, 63) and autism spectrum
disorder (64–66). Recent publications indicate a connection
between dysregulated synapse number, i.e., hyperconnectivity,
and symptoms of autism spectrum disorder (67); moreover,
lower plasma oxytocin levels have been reported in children
with autism and social impairments (68, 69). Those impairments
and low plasma oxytocin levels might be associated with an
altered composition of the gut microbiome (70), a process
that also impacts MEF2 phosphorylation (71), and neuronal
plasticity (72). A current study revealed that in male patients
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FIGURE 1 | Graphical Abstract of the proposed signaling scheme. Oxytocin binds its receptor, which transactivates different types of calcium channels, leading to
calcium influx from the extracellular space. Calcium activates protein kinase C, and subsequent MAPK pathway activation, i.e., MEK1/2-ERK1/2, which translocates
to the nucleus and activates the transcription factor CREB. Calcium also activates the calcium-dependent phosphatase calcineurin, which dephosphorylates and
therefore activates MEF2. Active MEF2 increases gene transcription of negative regulators of synaptic structures, causing decreased neurite outgrowth, synapse
number, and hypoconnectivity between neighboring neurons. As oxytocin receptor positive neurons are located within brain regions of the salience network, MEF2
activity regulates the connectivity within those regions, dampening or increasing the activity in the whole network. Depending on the emotional context of external
stimuli, those changes in the salience network can cause alleviating or adverse behavioral responses. The schematic art pieces used in this figure were provided by
Servier Medical art (http://servier.com/Powerpoint-image-bank). Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported
License.
with autism spectrum disorder higher levels of endogenous
salivary oxytocin are associated with lower degrees of functional
coupling between the amygdala and hippocampus (73). Notably,
a single dose of intranasal oxytocin induced a further reduction
in the degree of functional connectivity between those two
regions. Those data suggest that abnormal oxytocin synthesis
and/or intracerebral release could be the cause for the observed
connectivity differences in autistic patients. In support of this
hypothesis, we and others have recently shown that oxytocin
modulates neuronal morphology and synapse formation in
dependence of MEF2A, calcium signaling, and the MAPK
pathway (50, 74–78).
MEF2-DRIVEN MECHANISMS AFFECTING
NEURONAL CONNECTIVITY
In order to elucidate the underlying signaling pathways
explaining the manifold behavioral effects of oxytocin, we
have gathered evidence for a central role of the transcription
factor MEF2. The activity-dependent influence on neuronal
plasticity, termed metaplasticity, is one key characteristic trait of
MEF2 (54, 79), and could explain the multitude of behavioral
effects of oxytocin, by altering the connectivity, and therefore
activity, between neurons of brain regions that are part of
the salience network (e.g., within the mPFC, hypothalamus,
or amygdala). Altered activity within those oxytocin-sensitive
brain regions dampens or stimulates adjacent regions (80, 81),
and therefore the whole network. The molecular machinery
that determines MEF2 activity, and therefore causes this
plasticity, has been investigated in detail. MEF2 contains
several different phosphorylation sites, acting either inhibitory,
or stimulatory on gene transcription (52). Two different
calcium-dependent pathways have been described: (1) Class II
HDACs are bound to MEF2, acting as permanent inhibitors.
Upon calcium influx, these HDACs are phosphorylated by
calcium/calmodulin activated kinase (CaMK) and exported out
of the nucleus, relieving MEF2 repression and allowing for the
activation of MEF2-dependent transcription (58). (2) Calcium
influx leads to the dephosphorylation of MEF2 proteins at
serine 408, via the calcium-dependent phosphatase calcineurin
(60, 82). This dephosphorylation promotes a switch from
sumoylation to acetylation at lysine 403, which leads to
inhibition of dendritic claw differentiation (82). The question
remains how activated (acetylated and dephosphorylated) MEF2
regulates synapse number, and therefore connectivity between
neurons. Several possible mechanisms have been described:
first, activated MEF2 promotes the sumoylation and subsequent
degradation of a synaptic scaffolding protein, the postsynaptic
density protein 95 (PSD-95) (83). Second, the transcription of
negative regulators of synapse development, arc and synGAP, is
stimulated by activated MEF2, leading to a reduced excitatory
synapse number in hippocampal neurons (60). And lastly,
MEF2 closely interacts with another regulator of neuronal
connectivity, the mitochondria (79). We have shown that
MEF2 expression modulates the basic mitochondrial functions
like maximal respiration, spare respiratory capacity, and ATP
production in neurons by means of a CRISPR-Cas-generated
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MEF2A functional knockout cell line (51). Those mitochondrial
mechanisms are known to regulate synaptic strength (79). Since
mitochondria have their own genome, transcription factors like
MEF2 are able to induce mitochondrial gene transcription in
addition to nuclear transcription. Indeed, MEF2 promotes the
expression of the mitochondrial gene ND6, which is essential
for the function of the oxidative phosphorylation system (84),
which regulates the production of ROS. Release of ROS activates
the pro-apoptotic caspase-3, which induces the breakdown of
PSD-95, thereby weakening synaptic strength (79).
Taken together, the above-described effects of MEF2 on
synaptic strength can be bidirectional, as MEF2 can either
stimulate or inhibit gene transcription (85). Oxytocin receptor
signaling activates MEF2 in a context-dependent manner and
thereby induces morphological changes, e.g., neurite retraction
(50). Morphological changes in turn determine the synaptic
strength and therefore connectivity between oxytocin receptor
positive neurons (76). Oxytocin-sensitive neurons are located in
brain regions that are part of the salience network (80), which
has been shown to be responsive to oxytocin (42) and modulates
anxiety-like behavior or the stress response (86, 87).
CONCLUSION
In conclusion, oxytocin exerts its behavioral effects not in a direct
manner, but rather acts modulatory on the activated salience
network, to alter the emotional context of a secondary stimulus
and produce a variety of context-dependent behavioral outcomes,
including anxiolysis and anxiogenesis and increased or reduced
stress response. We hypothesize that MEF2 is one of the key
elements enabling this behavioral variability by modulating the
connectivity of oxytocin receptor-positive neurons within a brain
region and as result of this, potentially affecting the salience
network as a whole.
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